Skip to main content
SpringerLink
Log in

Shortening and De-Escalation of Dual Antiplatelet Therapy After PCI

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Abstract

Purpose of Review

Dual antiplatelet therapy (DAPT) for a period of 6 to 12 months constitutes the standard of care after percutaneous coronary intervention. Post-PCI DAPT leads to a decrease in rates of ischemic events at the expense of increased bleeding risk. This review article is aimed at discussing novel therapeutic strategies proposed to mitigate the bleeding risk associated with DAPT.

Recent Findings

Antiplatelet monotherapy after a short-term DAPT post-PCI has been shown to be a feasible and safe alternative. Recent studies have demonstrated that P2Y12 inhibitor monotherapy is associated with improved outcomes compared to DAPT or aspirin. Similarly, antiplatelet de-escalation to less potent P2Y12 inhibitors after a short period of more potent ones has shown promising data.

Summary

Recent data from large clinical trials have shifted the traditional paradigm of 6- or 12-month antiplatelet therapy after percutaneous coronary interventions. Antiplatelet regimens of shorter duration and variable intensity, based on individual risk factors, comorbidities and bleeding/ischemic risks, appear to be the next antiplatelet frontier post-PCI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Angiolillo DJ, Galli M, Collet JP, Kastrati A, O’Donoghue ML. Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention. 2022;17(17):e1371–96.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Bossavy JP, Thalamas C, Sagnard L, Barret A, Sakariassen K, Boneu B, et al. A double-blind randomized comparison of combined aspirin and ticlopidine therapy versus aspirin or ticlopidine alone on experimental arterial thrombogenesis in humans. Blood. 1998;92(5):1518–25.

    Article  CAS  PubMed  Google Scholar 

  3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.

    Article  CAS  PubMed  Google Scholar 

  4. CiUAtPRET I. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.

    Article  Google Scholar 

  5. Chen Z. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607–21.

  6. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411–20.

    Article  CAS  PubMed  Google Scholar 

  7. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352(12):1179–89.

    Article  CAS  PubMed  Google Scholar 

  8. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.

    Article  CAS  PubMed  Google Scholar 

  9. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.

    Article  CAS  PubMed  Google Scholar 

  10. Schüpke S, Neumann F-J, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381(16):1524–34.

    Article  PubMed  Google Scholar 

  11. •• Lawton JS, Tamis-Holland JE, Bangalore S, Bates ER, Beckie TM, Bischoff JM, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization. J Am Coll Cardiol. 2022;79(2):e21-e129. Latest revascularization guidelines

  12. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2018;40(2):87–165.

    Article  Google Scholar 

  13. Valle JA, Shetterly S, Maddox TM, Ho PM, Bradley SM, Sandhu A, et al. Postdischarge bleeding after percutaneous coronary intervention and subsequent mortality and myocardial infarction. Circ Cardiovasc Interv. 2016;9(6):e003519.

  14. Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019;40(31):2632–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017;39(3):213–60.

    Article  Google Scholar 

  16. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123–55.

    PubMed  Google Scholar 

  17. Bønaa KH, Mannsverk J, Wiseth R, Aaberge L, Myreng Y, Nygård O, et al. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016;375(13):1242–52.

    Article  PubMed  Google Scholar 

  18. Rymer JA, Harrison RW, Dai D, Roe MT, Messenger JC, Anderson HV, et al. Trends in bare-metal stent use in the United States in patients aged≥ 65 years (from the CathPCI Registry). Am J Cardiol. 2016;118(7):959–66.

    Article  PubMed  Google Scholar 

  19. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373(21):2038–47.

    Article  CAS  PubMed  Google Scholar 

  20. Ariotti S, Adamo M, Costa F, Patialiakas A, Briguori C, Thury A, et al. Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention? JACC: Cardiovascular Interventions. 2016;9(5):426–36.

  21. Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrié D, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. The Lancet. 2018;391(10115):41–50.

    Article  CAS  Google Scholar 

  22. Mehran R, Cao D, Angiolillo DJ, Bangalore S, Bhatt DL, Ge J, et al. 3-or 1-month DAPT in patients at high bleeding risk undergoing everolimus-eluting stent implantation. Cardiovascular Interventions. 2021;14(17):1870–83.

    Article  PubMed  Google Scholar 

  23. Windecker S, Latib A, Kedhi E, Kirtane AJ, Kandzari DE, Mehran R, et al. Polymer-based or polymer-free stents in patients at high bleeding Risk. N Engl J Med. 2020;382(13):1208–18.

    Article  CAS  PubMed  Google Scholar 

  24. Kirtane AJ, Stoler R, Feldman R, Neumann F-J, Boutis L, Tahirkheli N, et al. Primary results of the EVOLVE short DAPT study. Circ Cardiovasc Interv. 2021;14(3):e010144.

  25. Hahn J-Y, Song YB, Oh J-H, Chun WJ, Park YH, Jang WJ, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA. 2019;321(24):2428–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321(24):2414–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Watanabe H, Morimoto T, Natsuaki M, Yamamoto K, Obayashi Y, Ogita M, et al. Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial. JAMA Cardiology. 2022;7(4):407–17.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Valgimigli M, Frigoli E, Heg D, Tijssen J, Jüni P, Vranckx P, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021;385(18):1643–55.

    Article  CAS  PubMed  Google Scholar 

  29. Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940–9.

    Article  CAS  PubMed  Google Scholar 

  30. Franzone A, McFadden E, Leonardi S, Piccolo R, Vranckx P, Serruys PW, et al. Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting. J Am Coll Cardiol. 2019;74(18):2223–34.

    Article  CAS  PubMed  Google Scholar 

  31. • Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. New England J Med. 2019;381(21):2032–42. Large study showing that ticagrelor monotherapy was associated with lower incidence of clinically relevant bleeding with no higher risk of death, myocardial infarction, or stroke.

  32. Valgimigli M, Mehran R, Franzone A, da Costa BR, Baber U, Piccolo R, et al. Ticagrelor monotherapy versus dual-antiplatelet therapy after PCI: an individual patient-level meta-analysis. JACC: Cardiovascular Interventions. 2021;14(4):444–56.

  33. Kim B-K, Hong S-J, Cho Y-H, Yun KH, Kim YH, Suh Y, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA. 2020;323(23):2407–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Kogame N, Guimarães PO, Modolo R, De Martino F, Tinoco J, Ribeiro EE, et al. Aspirin-free prasugrel monotherapy following coronary artery stenting in patients with stable CAD: The ASET Pilot Study. JACC: Cardiovasc Interv. 2020;13(19):2251–62.

  35. • Gragnano F, Mehran R, Branca M, Franzone A, Baber U, Jang Y, et al. P2Y12 inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions. J Am Coll Cardiol. 2023;81(6):537–52. Recent study demonstrating the effectiveness of short DAPT in patients undergoing complex PCI.

  36. Cuisset T, Deharo P, Quilici J, Johnson TW, Deffarges S, Bassez C, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J. 2017;38(41):3070–8.

    Article  CAS  PubMed  Google Scholar 

  37. Kim CJ, Park MW, Kim MC, Choo EH, Hwang BH, Lee KY, et al. Unguided de-escalation from ticagrelor to clopidogrel in stabilised patients with acute myocardial infarction undergoing percutaneous coronary intervention (TALOS-AMI): an investigator-initiated, open-label, multicentre, non-inferiority, randomised trial. Lancet. 2021;398(10308):1305–16.

    Article  CAS  PubMed  Google Scholar 

  38. Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet. 2017;390(10104):1747–57.

    Article  CAS  PubMed  Google Scholar 

  39. Claassens DMF, Vos GJA, Bergmeijer TO, Hermanides RS, van ’t Hof AWJ, van der Harst P, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. New England J Med. 2019;381(17):1621–31.

  40. • Laudani C, Greco A, Occhipinti G, Ingala S, Calderone D, Scalia L, et al. Short duration of DAPT versus de-escalation after percutaneous coronary intervention for acute coronary syndromes. JACC Cardiovasc Interv. 2022;15(3):268–77. Study comparing short DAPT to de-escalation strategy.

  41. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2020;42(14):1289–367.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Valve and Structural Heart Disease, Minneapolis Heart Institute, 800 East 28Th Street, 2Nd Floor, Minneapolis, MN, 55407, USA

    Konstantinos V. Voudris MD, PhD

  2. Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY, USA

    Dmitriy N. Feldman MD

Authors
  1. Konstantinos V. Voudris MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dmitriy N. Feldman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Konstantinos V. Voudris MD, PhD.

Ethics declarations

Conflict of Interest

Konstantinos V. Voudris and Dmitriy N. Feldman declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Voudris, K.V., Feldman, D.N. Shortening and De-Escalation of Dual Antiplatelet Therapy After PCI. Curr Treat Options Cardio Med 25, 127–141 (2023). https://doi.org/10.1007/s11936-023-00981-w

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-023-00981-w

Keywords

Search

Navigation